Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05998642 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 52 words
    • Site details revised at 2 of 8 sites
  2. Site details revised at 1 of 8 sitesv15
  3. Study sites: 7 to 8v14
  4. Eligibility criteria expanded, about 261 wordsv13
  5. Study sites: 6 to 7v12
Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 5 to 6v11
  2. Site details revised at 1 of 5 sitesv10
  3. Study sites: 4 to 5v9
  4. Study sites revised (4)v8
  5. Eligibility criteria expanded, about 138 wordsv7
  6. Start date: Nov 30, 2023 to Feb 13, 2024v6
  7. Study sites: 3 to 4v5
  8. Site details revised at 1 of 3 sitesv4
  9. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Sep 30, 2023 to Nov 30, 2023
    v3
  10. Study description expanded, about 1 wordv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as the care most people get for Primary Central Nervous System Lymphoma (PCNSL).
Trial Details
NCT Number NCT05998642
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Janssen Inc.
Conditions
(from sponsor)		 Non-hodgkin Lymphoma
Related terms Lymphoma, Non-Hodgkin
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov